|
StemCyte®, Inc. Surpasses 200th Cord Blood Stem Cell Transplant Leading Breakthrough Clinical Study for Thalassemia in Taiwan | |||
|
|
July 27, 2005 | StemCyte has now provided cord blood units to over 130 transplant centers worldwide across 6 continents, and the number of units released for transplantation is rapidly increasing. | ||
| ARCADIA, Calif., July 26 /PRNewswire/ -- StemCyte, Inc., a privately held stem cell therapy and cord blood bank, contributed its 200th cord blood unit for transplant last month, marking another milestone in the company's growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 80 transplant centers worldwide across 5 continents, and the number of units released for transplantation is rapidly increasing.
Cord blood stem cell units are increasingly becoming a viable alternative to bone marrow transplants for the treatment of over 70 diseases, including leukemias, lymphomas, immune diseases and genetic disorders. 'This is an especially exciting time for the cord blood stem cell industry as now more and more transplant centers are using cord blood for both children and adult transplantations,' says StemCyte's CEO Ken Giacin. 'We are also seeing broader application beyond leukemia. We recently provided StemCyte cord blood stem cell units for ten children with thalassemia for the largest unrelated cord blood transplant clinical study for this disease in Taiwan, and achieved an unprecedented 90% engraftment. Similar to sickle cell anemia, thalassemia is a debilitating blood disease, which affects both the patient's quality of life and life expectancy and affects hundreds of thousands of patients a year worldwide, especially in Asia, the Middle East and the Mediterranean regions. We are extremely proud to be leading this life saving effort to potentially cure these diseases.' In addition, StemCyte's family cord blood bank and wholly-owned subsidiary, Cord Blood FamilyTrust(TM), allows families the ability to privately store their own baby's cord blood using the same laboratory, professional staff and proprietary processes as their highly accredited public bank. 'At Cord Blood FamilyTrust, we are extremely proud to be an important part of the StemCyte lifesaving mission,' stresses Cord Blood FamilyTrust President and CEO Dave Dickinson about the customers' advantages of this unique connection. 'It is very difficult for other family cord blood banks to gain much transplant experience as, fortunately, the odds of a baby or their sibling needing a transplant unit in their early years is extremely low. Our customers understand that the best way to judge a family cord blood bank is to determine if their units will work in a life-saving situation, and we are learning how critical it is to work closely with a wide range of transplant centers as their protocols and methods vary. With Cord Blood FamilyTrust, families are now able to store their own baby's cord blood with a transplant- physician-trusted stem cell provider.' To find out more visit StemCyte online at www.stemcyte.com or Cord Blood FamilyTrust at www.cordbloodfamily.com. About StemCyte, Inc. StemCyte, Inc., headquartered in Arcadia, California, intends to create the largest donor umbilical cord blood stem cell bank in the world. StemCyte and its subsidiaries are dedicated to providing high quality, cost-effective, stem cell transplantation and therapy to all patients in need. StemCyte, Inc.'s management team consists of medical, scientific, clinical laboratory, tissue typing, blood banking and stem cell professionals and experts, most of whom have been recruited from world-renowned medical institutions such as Harvard Medical School, UCLA, American Red Cross, City of Hope, and others. Because of its ability to deliver high quality and high quantity viable cord blood stem cells, StemCyte is a key choice for transplant centers around the world. StemCyte has provided cord blood units to hospitals and transplant centers in the United States as well as in Australia, Brazil, Canada, France, Great Britain, Hong Kong, Israel, Japan, Malaysia, Mexico, Singapore, Spain and Taiwan. StemCyte donor banks have now supplied cord blood units for more than 200 life-saving transplants. About Cord Blood FamilyTrust Cord Blood FamilyTrust, the family subsidiary of StemCyte, Inc., uses the same StemCyte International Cord Blood Center laboratory as the public bank and shares its leading-edge stem cell optimization process. This process is monitored by over 400 quality-based procedures and assures that more than 90% of collected nucleated cells will be retained after collection. CONTACT: |
||||
 |
|
